Tumor PD-L1 engages myeloid PD-1 to suppress type I interferon to impair cytotoxic T lymphocyte recruitment
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tumor PD-L1 engages myeloid PD-1 to suppress type I interferon to impair cytotoxic T lymphocyte recruitment
Authors
Keywords
-
Journal
CANCER CELL
Volume 41, Issue 3, Pages 620-636.e9
Publisher
Elsevier BV
Online
2023-03-13
DOI
10.1016/j.ccell.2023.02.005
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Single-Cell RNA Sequencing Reveals the Tissue Architecture in Human High-Grade Serous Ovarian Cancer
- (2022) Junfen Xu et al. CLINICAL CANCER RESEARCH
- Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer
- (2022) Harry H. Yoon et al. JAMA Oncology
- Loss of type I IFN responsiveness impairs natural killer cell antitumor activity in breast cancer
- (2021) Damien J. Zanker et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- CD169+ lymph node macrophages have protective functions in mouse breast cancer metastasis
- (2021) Carlotta Tacconi et al. Cell Reports
- PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity
- (2021) Joseph M. Gozgit et al. CANCER CELL
- A single-cell and spatially resolved atlas of human breast cancers
- (2021) Sunny Z. Wu et al. NATURE GENETICS
- Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer
- (2021) Yuanyuan Zhang et al. CANCER CELL
- ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity
- (2020) John Alec Moral et al. NATURE
- Pembrolizumab for Early Triple-Negative Breast Cancer
- (2020) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant checkpoint blockade for cancer immunotherapy
- (2020) Suzanne L. Topalian et al. SCIENCE
- Targeted deletion of PD-1 in myeloid cells induces antitumor immunity
- (2020) Laura Strauss et al. Science Immunology
- PD-1+ natural killer cells in human non-small cell lung cancer can be activated by PD-1/PD-L1 blockade
- (2020) Marcel P. Trefny et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Prostate cancer cell‐intrinsic interferon signaling regulates dormancy and metastatic outgrowth in bone
- (2020) Katie L Owen et al. EMBO REPORTS
- Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy
- (2020) Maud Mayoux et al. Science Translational Medicine
- The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes
- (2020) Floris Dammeijer et al. CANCER CELL
- PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade
- (2020) Qi Peng et al. Nature Communications
- Opposing Roles of Type I Interferons in Cancer Immunity
- (2020) Giselle M. Boukhaled et al. Annual Review of Pathology-Mechanisms of Disease
- An Interferon-Driven Oxysterol-Based Defense against Tumor-Derived Extracellular Vesicles
- (2019) Angelica Ortiz et al. CANCER CELL
- Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy
- (2019) Imran Siddiqui et al. IMMUNITY
- Single-Cell Transcriptomics of Human and Mouse Lung Cancers Reveals Conserved Myeloid Populations across Individuals and Species
- (2019) Rapolas Zilionis et al. IMMUNITY
- Clonal replacement of tumor-specific T cells following PD-1 blockade
- (2019) Kathryn E. Yost et al. NATURE MEDICINE
- Type I interferon suppresses tumor growth through activating the STAT3-granzyme B pathway in tumor-infiltrating cytotoxic T lymphocytes
- (2019) Chunwan Lu et al. Journal for ImmunoTherapy of Cancer
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Site‐specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti–PD‐1 therapy
- (2019) Ines Pires da Silva et al. CANCER
- Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade
- (2019) Imran G. House et al. CLINICAL CANCER RESEARCH
- SHP2 inhibition reduces leukemogenesis in models of combined genetic and epigenetic mutations
- (2019) Ruchi Pandey et al. JOURNAL OF CLINICAL INVESTIGATION
- Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade
- (2019) Juan C. Osorio et al. JOURNAL OF CLINICAL ONCOLOGY
- Visualizing structure and transitions in high-dimensional biological data
- (2019) Kevin R. Moon et al. NATURE BIOTECHNOLOGY
- An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
- (2018) Jianfang Liu et al. CELL
- PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression
- (2018) Haidong Tang et al. JOURNAL OF CLINICAL INVESTIGATION
- Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression
- (2018) Heng Lin et al. JOURNAL OF CLINICAL INVESTIGATION
- Myeloid-targeted immunotherapies act in synergy to induce inflammation and antitumor immunity
- (2018) Curtis J. Perry et al. JOURNAL OF EXPERIMENTAL MEDICINE
- IFNAR1 Controls Autocrine Type I IFN Regulation of PD-L1 Expression in Myeloid-Derived Suppressor Cells
- (2018) Wei Xiao et al. JOURNAL OF IMMUNOLOGY
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
- (2018) Patrick M. Forde et al. NEW ENGLAND JOURNAL OF MEDICINE
- LFA-1 in T Cell Migration and Differentiation
- (2018) Brandon L. Walling et al. Frontiers in Immunology
- Single-cell analysis reveals that stochasticity and paracrine signaling control interferon-alpha production by plasmacytoid dendritic cells
- (2018) Florian Wimmers et al. Nature Communications
- Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
- (2018) S Adams et al. ANNALS OF ONCOLOGY
- PD-1 Blockade in Early-Stage Lung Cancer
- (2018) Samuel Rosner et al. Annual Review of Medicine
- A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
- (2018) Livnat Jerby-Arnon et al. CELL
- Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma
- (2018) Diwakar Davar et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity
- (2017) Vikram R. Juneja et al. JOURNAL OF EXPERIMENTAL MEDICINE
- ILC2s regulate adaptive Th2 cell functions via PD-L1 checkpoint control
- (2017) Christian Schwartz et al. JOURNAL OF EXPERIMENTAL MEDICINE
- PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
- (2017) Sydney R. Gordon et al. NATURE
- T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
- (2017) Enfu Hui et al. SCIENCE
- Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice
- (2017) Janet Lau et al. Nature Communications
- Neoadjuvant Interferons: Critical for Effective PD-1–Based Immunotherapy in TNBC
- (2017) Natasha K. Brockwell et al. Cancer Immunology Research
- Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC
- (2017) Paul C. Tumeh et al. Cancer Immunology Research
- A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-α-2b in patients with CEA-expressing carcinomas
- (2016) Megan C. Duggan et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer
- (2016) Thomas A Mace et al. GUT
- Near-optimal probabilistic RNA-seq quantification
- (2016) Nicolas L Bray et al. NATURE BIOTECHNOLOGY
- Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
- (2016) Vassiliki A. Boussiotis NEW ENGLAND JOURNAL OF MEDICINE
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
- (2016) Daniel Sanghoon Shin et al. Cancer Discovery
- Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth
- (2015) Sonja Kleffel et al. CELL
- Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma
- (2015) Ahmad A. Tarhini et al. Journal of Translational Medicine
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade
- (2015) Juan Fu et al. Science Translational Medicine
- Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma
- (2014) John C Castle et al. BMC GENOMICS
- Targeting the Tumor Microenvironment with Interferon-β Bridges Innate and Adaptive Immune Responses
- (2014) Xuanming Yang et al. CANCER CELL
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Mechanisms Governing Metastatic Dormancy and Reactivation
- (2013) Filippo G. Giancotti CELL
- Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape
- (2012) Bradley N Bidwell et al. NATURE MEDICINE
- clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters
- (2012) Guangchuang Yu et al. OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY
- Interferon Alpha Adjuvant Therapy in Patients With High-Risk Melanoma: A Systematic Review and Meta-analysis
- (2010) S. Mocellin et al. JNCI-Journal of the National Cancer Institute
- PD-1 on dendritic cells impedes innate immunity against bacterial infection
- (2009) S. Yao et al. BLOOD
- CD4+ T Cells Regulate Pulmonary Metastasis of Mammary Carcinomas by Enhancing Protumor Properties of Macrophages
- (2009) David G. DeNardo et al. CANCER CELL
- Combined treatment with pegylated interferon-α-2a and dacarbazine in patients with advanced metastatic melanoma
- (2008) Axel Hauschild et al. CANCER
- Tumor-Targeted Interferon-α Delivery by Tie2-Expressing Monocytes Inhibits Tumor Growth and Metastasis
- (2008) Michele De Palma et al. CANCER CELL
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now